These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 17341534)
1. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534 [TBL] [Abstract][Full Text] [Related]
2. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366 [TBL] [Abstract][Full Text] [Related]
3. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. Bork JA; Rogers T; Wedlund PJ; de Leon J J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802 [TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051 [TBL] [Abstract][Full Text] [Related]
5. Is pharmacogenetic CYP2D6 testing useful? Vetti HH; Molven A; Eliassen AK; Steen VM Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842 [TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325 [TBL] [Abstract][Full Text] [Related]
8. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707 [TBL] [Abstract][Full Text] [Related]
9. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Sjöqvist F; Eliasson E Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719 [TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotypes in Puerto Rican psychiatry patients with intolerance of antidepressants and antipsychotics. Gonzalez-Tejera GM; Corey S Bol Asoc Med P R; 2009; 101(1):7-12. PubMed ID: 19954080 [TBL] [Abstract][Full Text] [Related]
11. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Ieiri I; Yamada S; Seto K; Morita T; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354 [TBL] [Abstract][Full Text] [Related]
12. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765 [TBL] [Abstract][Full Text] [Related]
13. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism]. Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S Encephale; 2000; 26(1):62-7. PubMed ID: 10875063 [TBL] [Abstract][Full Text] [Related]
14. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795 [TBL] [Abstract][Full Text] [Related]
15. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Chen S; Chou WH; Blouin RA; Mao Z; Humphries LL; Meek QC; Neill JR; Martin WL; Hays LR; Wedlund PJ Clin Pharmacol Ther; 1996 Nov; 60(5):522-34. PubMed ID: 8941025 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics and psychoactive drug therapy: ready for the patient? Steimer W Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233 [TBL] [Abstract][Full Text] [Related]
17. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. Vandel P World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic potential of psychiatric medications and CYP2D6. Foley KF; Quigley DI MLO Med Lab Obs; 2010 Jan; 42(1):32-4. PubMed ID: 20180465 [TBL] [Abstract][Full Text] [Related]
19. Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients. González-Tejera G; Gaedigk A; Corey S P R Health Sci J; 2010 Sep; 29(3):299-304. PubMed ID: 20799519 [TBL] [Abstract][Full Text] [Related]
20. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Jerling M; Dahl ML; Aberg-Wistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjöqvist F Clin Pharmacol Ther; 1996 Apr; 59(4):423-8. PubMed ID: 8612387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]